Baxter launches in the EU Olimel N12, a new addition to the company�s olive oil-based parenteral nutrition
Baxter International Inc. a global leader in clinical nutrition, announced the European launch of Olimel N12, the new addition to the company’s olive oil-based parenteral nutrition (PN) triple-chamber bag portfolio. The European launch will be at the 41st Congress of the European Society of Clinical Nutrition and Metabolism (ESPEN).
Olimel N12 combines a high protein formulation with low glucose content, resulting in the lowest energy to protein ratio currently available in a standardized, triple-chamber bag. The new formulation contains: 76g of amino acid per liter, designed to meet protein targets in lower fluid volumes. Only 73g of glucose per liter, helping to reduce the potential glycemic load and subsequent risk of hyperglycemia. An olive oil-based lipid emulsion, which may preserve immune function.
The fact that 50% of critically ill patients do not receive adequate nutritional intake poses a challenge. Both ESPEN and the American Society for Parenteral and Enteral Nutrition (ASPEN) recommend a higher protein intake for this patient group, with reduced calorie. These patients are also often restricted in the amount of fluid they can receive. Critical illness is associated with rapid protein breakdown and muscle loss. Studies have shown that optimal nutrition, involving both moderate energy intake and high protein supply, is associated with reduced mortality.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma